Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug

MT Newswires Live

2024/11/21

Kura Oncology (KURA) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer.

Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies.

It will also be eligible for $741 million on achieving development, regulatory and commercial milestones, the companies added.

Under the agreement, the companies will jointly develop and commercialize the drug in the US, while Kyowa Kirin will hold exclusive commercialization rights outside the US.

Kura stock fell 15% in recent after-hours activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485099172"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485099172\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485099172?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485099172","market":"hk","top_or_hot":-1,"title":"Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> Kura Oncology (KURA) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer.</p><p>Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies.</p><p>It will also be eligible for $741 million on achieving development, regulatory and commercial milestones, the companies added.</p><p>Under the agreement, the companies will jointly develop and commercialize the drug in the US, while Kyowa Kirin will hold exclusive commercialization rights outside the US.</p><p>Kura stock fell 15% in recent after-hours activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-21 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kura Oncology (KURA) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer.</p><p>Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies.</p><p>It will also be eligible for $741 million on achieving development, regulatory and commercial milestones, the companies added.</p><p>Under the agreement, the companies will jointly develop and commercialize the drug in the US, while Kyowa Kirin will hold exclusive commercialization rights outside the US.</p><p>Kura stock fell 15% in recent after-hours activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485099172","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485099172","pubTimestamp":1732142775,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kura Oncology  and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer.Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies.It will also be eligible for $741 million on achieving development, regulatory and commercial milestones, the companies added.Under the agreement, the companies will jointly develop and commercialize the drug in the US, while Kyowa Kirin will hold exclusive commercialization rights outside the US.Kura stock fell 15% in recent after-hours activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","KURA":"Kura Oncology, Inc"},"translate_title":"Kura Oncology与Kyowa Kirin共同开发血癌药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURA":1},"content_text":"Kura Oncology (KURA) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer.Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies.It will also be eligible for $741 million on achieving development, regulatory and commercial milestones, the companies added.Under the agreement, the companies will jointly develop and commercialize the drug in the US, while Kyowa Kirin will hold exclusive commercialization rights outside the US.Kura stock fell 15% in recent after-hours activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}